Munich – Allecra Therapeutics, an antibiotics developer from the European BioValley life sciences cluster in the upper Rhine Valley, has completed a Series B round of financing totalling EUR 22 million. Investors include the Dutch life sciences venture capital financier Forbion Capital Partners, Paris-based Edmond de Rothschild Investment Partners and EMBL Ventures from Heidelberg. This group of investors previously financed the formation of Allecra Therapeutics by providing EUR 15 million in 2013.
A team from CMS Germany headed by Munich-based partner Stefan-Ulrich Müller advised the investor group on legal aspects of the financing. The investors are long-standing clients of CMS Germany.
Allecra Therapeutics develops antibiotics against multidrug-resistant Gram-negative bacteria. The new capital is earmarked primarily for a phase II study of the most advanced candidate drug compound, AAI202, scheduled to commence in the first half of 2017. AAI202 is a combination drug mainly intended to combat infections with ESBL bacteria that are occurring with increasing frequency in hospitals.
CMS Hasche Sigle
Stefan-Ulrich Müller, Lead Partner
Dr Tilman Weichert, Counsel
Dr Tobias Kallmaier, Senior Associate
Klara Brütting, Associate, all Venture Capital
Roland Wutzke, Partner, Tax